Related Experiment Video

Updated: May 6, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.1K

Expression, characterization, and evaluation of a RANK-binding single chain fraction variable: an osteoclast

Madhuri Newa1, Michael Lam, Krishna Hari Bhandari

  • 1Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8, Canada.

Molecular Pharmaceutics
|November 1, 2013
PubMed

Insights

Researchers developed a single-chain variable fragment (scFv) targeting RANK receptors on osteoclasts. This targeted approach shows potential for treating bone resorption diseases by inhibiting osteoclast activity without cytotoxicity.

Area of Science:

  • Biotechnology
  • Immunology
  • Molecular Biology

Background:

  • Osteoclasts are key cells in bone resorption, expressing Receptor Activator of Nuclear factor Kappa B (RANK) receptors.
  • Targeting osteoclasts offers a therapeutic strategy for bone resorption diseases.
  • Single-chain variable fragments (scFv) provide antibody-like specificity for targeted therapies.

Purpose of the Study:

  • To express, characterize, and evaluate an scFv targeting RANK receptors.
  • To assess the scFv's potential as a platform for targeting osteoclasts.
  • To investigate the therapeutic potential of anti-RANK scFv for resorptive bone diseases.

Main Methods:

  • Phage display technology for scFv expression.
  • Characterization using DNA sequencing, SDS-PAGE, MALDI-TOF, ELISA, Western blot, and immunocytochemistry.
  • Evaluation of cytotoxicity (MTT assay), cross-reactivity (ELISA), osteoclast targeting (immunocytochemistry), and anti-resorptive efficacy (TRAP and resorption assays).

Main Results:

  • Successfully expressed and characterized anti-RANK scFv.
  • Demonstrated no cross-reactivity with other tumor necrosis factor receptor (TNFR) members.
  • Showed specificity for RANK receptors, no cytotoxicity on non-RANK bearing cells, and inhibited osteoclast activity.

Conclusions:

  • The developed anti-RANK scFv is specific, non-cytotoxic, and effectively inhibits osteoclast activity.
  • This scFv can serve as a drug delivery platform for targeting osteoclasts.
  • Offers a promising therapeutic strategy for resorptive bone diseases.

More Related Videos

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro07:03

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro

Published on: June 16, 2022

6.6K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

8.8K

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
3.7K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
167
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
175
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139